Patent ID: 9238844
Filing Date: 2016-01-19
CPC Classification: C12Q

Claim Text:
1. A method of determining the amount of Influenza A virus resistant to a first and a second antiviral composition in a sample, the sample comprising a mixture of Influenza A virus particles that may be resistant or sensitive to the first and the second antiviral compositions, the method comprising: subjecting a first amplification mixture to nucleic acid amplification wherein the mixture comprises the sample and a first oligonucleotide capable of binding to a first marker having a sequence of SEQ ID NO. 20, wherein the first oligonucleotide amplifies wild-type and mutant alleles of the first marker with different amplification efficiencies, wherein the different amplification efficiencies arise from a mismatch nucleotide sequence between the first oligonucleotide and the wild-type or mutant alleles of the first marker; determining a difference between a Ct value of Influenza A virus resistant to the first antiviral composition (Ct subjecting a second amplification mixture to nucleic acid amplification wherein the mixture comprises the sample and a second oligonucleotide capable of binding to a second marker having a sequence of SEQ ID NO. 22, wherein the second oligonucleotide amplifies wild-type and mutant alleles of the second marker with different amplification efficiencies, wherein the different amplification efficiencies arise from a mismatch nucleotide sequence between the first oligonucleotide and the wild-type or mutant alleles of the second marker; determining a difference between a Ct value of Influenza A virus resistant to the second antiviral composition (Ct determining the amount of Influenza A virus resistant to the first and second antiviral compositions (% mutant) in the first and second mixtures, respectively, with the equation: wherein the amount of Influenza A virus resistant to the first and second antiviral compositions in the first and second mixtures, respectively, is used to determine which antiviral compositions are effective against the Influenza A virus in the sample; wherein the first oligonucleotide added to the first mixture includes a sequence selected from the group consisting of SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4, SEQ ID NO. 5, SEQ ID NO. 6, SEQ ID NO. 7, SEQ ID NO. 8, SEQ ID NO. 9, SEQ ID NO. 10, SEQ ID NO. 11, SEQ ID NO. 12, SEQ ID NO. 13, and SEQ ID NO. 14; wherein the first oligonucleotide added to the second mixture includes a sequence selected from the group consisting of SEQ ID NO. 15, SEQ ID NO. 16, SEQ ID NO. 17, and SEQ ID NO. 18; and wherein the sample comprises a nucleic acid.